Kristen Fortney - 18 Feb 2025 Form 4 Insider Report for BioAge Labs, Inc. (BIOA)

Role
Chief Executive Officer, Director
Signature
/s/ Dov A. Goldstein as attorney-in-fact
Issuer symbol
BIOA
Transactions as of
18 Feb 2025
Net transactions value
$0
Form type
4
Filing time
20 Feb 2025, 16:17:02 UTC
Previous filing
25 Sep 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIOA Stock Option (Right to Buy) Award $0 +530,000 $0.000000 530,000 18 Feb 2025 Common Stock 530,000 $4.38 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.